P3-Type K0.45Co1/12Mg1/12Mn5/6O2 as a Superior Cathode Material for Potassium-Ion Batteries with High Structural Reversibility Ensured by the Co–Mg Co-Substitution

Mn-based layered oxides, as potential cathodes for potassium-ion batteries (PIBs), face major challenges such as consecutive phase transition, serious capacity loss, and sluggish K + transport kinetics. Herein, Co–Mg co-substituted...

Фазовый переход полупроводник-металл и "тристабильное" электрическое переключение в нанокристаллических пленках оксида ванадия на кремнии

It has been found at measurements on alternating current that the loop of a thermal hysteresis of semiconductor–metal phase transition in vanadium dioxide VO2 has the asymmetrical multistage form. On a direct current the complex shape of a hysteresis loop wasn't shown. Such behavior for VO2 films can be defined by heterophase nanocrystal structure of vanadium oxide and different type of charge carriers in grains volume and surfaces. The phenomenon is connected with consecutive phase transition in groups of nanocrystallites of the close size. In such films electrical switching with the "tristate" mode for the first time is revealed.

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more ef-fective and safer than single-agent thalidomide or lenalidomide.